Common use of Publications and Presentations Clause in Contracts

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees or consultants wishing to make a publication shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with such consultant) prior to submission for publication or presentation, (ii) the reviewing Party shall have the right to require a delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information in any such proposed publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-ownership shall be determined in accordance with customary standards. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (60) and ninety (90) day periods set forth in clauses (i) and (ii) above.

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDCJDC until such time as the JSC determines that the Publication Committee shall report to a different entity. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees or consultants wishing to make a publication shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with such consultant) prior to submission for publication or presentation, (ii) the reviewing Party shall have the right to require a delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information in any such proposed publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-ownership shall be determined in accordance with customary standards. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (60) and ninety (90) day periods set forth in clauses (i) and (ii) above. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of In the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees or consultants wishing event Biogen wishes to make a publication or public presentation related to this Agreement, Biogen shall deliver to the other Party Intec Pharma a copy of the proposed written publication or an outline of an the proposed oral disclosure presentation at least thirty (30) days (or, in the case of consulting or Third Party research agreements, such shorter period as required by the consulting or other research agreement) prior to submission for publication or presentation. Intec Pharma shall have the right to delay such proposed publication or presentation for up to sixty (60) days (or, in the case of consulting or Third Party research agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with research agreement) in order to file patent applications protecting Intec Pharma’s rights in any information included in such consultant) prior to submission for proposed publication or presentationpresentation to the extent such filings are consistent with Section 7.1.1 (Intec Pharma Prosecution Rights), (ii) the reviewing Party and Intec Pharma shall have the right to require a delay of up to ninety (90) days (or, in request the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting removal or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure redaction of any of its Confidential Information in any such proposed publication or presentation. In Intec Pharma shall not make any permitted publication or public presentation by a Partyrelated to this Agreement or any activities hereunder, except for such publications or public presentations that (a) relate solely to the general applicability of the Accordion Pill System and (b) do not directly or indirectly identify Biogen, the other Party’s contribution shall be duly recognizedProduct, and co-ownership shall be determined in accordance with customary standardsthe Agreement “[***]” Technology or any specific activities conducted under the Research Plan. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (60) and ninety (90) day periods set forth in clauses (i) and (ii) above“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

Publications and Presentations. The BioNTech shall have the sole right, either itself or through its Affiliates or Sublicensees, to present or publish the results of, or scientific information relating to, any activities under this Agreement PROVIDED THAT prior to the [***] the Parties acknowledge that will agree through the JSC on the content of any publications relating to the [***] and/or [***]. Biotheus shall not make any publication or presentation relating to a Licensed Compound or Licensed Product without the prior written consent of BioNTech. If, in accordance with the requirements and limitations of this Section 10.3 (Publications and Presentations), a Party desires to publicly present or publish results or scientific and medical publications and presentations will be made in information relating to a manner consistent with Third Party agreements in effect as Licensed Compound or Licensed Product which publication contains the Confidential Information of the Effective Date and industry standards for non-publishing Party, prior to doing so, the development and Commercialization publishing Party will provide non-publishing Party with drafts of drugs in the Fieldproposed abstracts, but must be strictly monitored to prevent any adverse effect from premature manuscripts or summaries of presentations that include such results or information. The non-publishing Party will respond no later than [***] days after receipt of such proposed publication or dissemination of results of the activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees presentation or consultants wishing to make a publication shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required may be agreed to by the consulting or other agreement with such consultant) prior to submission for publication or presentation, (ii) the reviewing Parties. The publishing Party shall have the right to require a will delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information in any such proposed publication or presentation. In any permitted presentation for a period up [***] days after the non-publishing Party receives such proposed publication or presentation to permit the non-publishing Party to make filings for patent protection and will otherwise remove its Confidential Information identified by a Party, the other Party’s contribution shall be duly recognized, and conon-ownership shall be determined publishing Party in such publication or presentation. The Parties agree to acknowledge the contributions of one another in accordance with customary standardsstandard academic practice regarding authorship of scientific publication. In negotiating consulting agreementsEach Party agrees to comply, each Party shall use Commercially Reasonable Efforts with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party; provided that any listings or publications made pursuant to this Section 10.3 (Publications and Presentations). [***] will provide such assistance as [***] may reasonably require to obtain the agreement of the consultant any consent or permission that may be required in order to the sixty (60) and ninety (90) day periods set forth in clauses (i) and (ii) abovepublish data that originates from [***].

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of In the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees or consultants wishing event “[***]” wishes to make a publication or public presentation related to this Agreement, “[***]” shall deliver to the other Party Intec Pharma a copy of the proposed written publication or an outline of an the proposed oral disclosure presentation at least thirty (30) days (or, in the case of consulting or Third Party research agreements, such shorter period as required by the consulting or other research agreement) prior to submission for publication or presentation. Intec Pharma shall have the right to delay such proposed publication or presentation for up to sixty (60) days (or, in the case of consulting or Third Party research agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with research agreement) in order to file patent applications protecting Intec Pharma’s rights in any information included in such consultant) prior to submission for proposed publication or presentationpresentation to the extent such filings are consistent with Section 7.1.1 (Intec Pharma Prosecution Rights), (ii) the reviewing Party and Intec Pharma shall have the right to require a delay of up to ninety (90) days (or, in request the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting removal or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure redaction of any of its Confidential Information in any such proposed publication or presentation. In Intec Pharma shall not make any permitted publication or public presentation by a Partyrelated to this Agreement or any activities hereunder, except for such publications or public presentations that (a) relate solely to the general applicability of the Accordion Pill System and (b) do not directly or indirectly identify “[***]”, the other Party’s contribution shall be duly recognizedProduct, and co-ownership shall be determined in accordance with customary standardsthe Agreement “[***]”Technology or any specific activities conducted under the Research Plan. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (60) and ninety (90) day periods set forth in clauses (i) and (ii) above“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.